Galderma Group Research Development Over Time

Stocks . Switzerland . 
Stock . Galderma Group N
GALD Stock   145.70  1.60  1.11%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Galderma Group Performance and Galderma Group Correlation.
  
Research Development is likely to drop to about 226.6 M in 2026.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Galderma Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Galderma Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Galderma Group's market price signifies the transaction level at which participants voluntarily complete trades.
Apply

Cross Equities Research Development Analysis

Compare Galderma Group N and related stocks such as Chocoladefabriken Lindt, Chocoladefabriken Lindt, and Barry Callebaut AG Research Development Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
20102011201220132014201520162017201820192020202120222023202420252026
LISP6.1 M8.3 M8.3 M8.3 M9.5 M10.5 M11.6 M12.7 M13.8 M14.7 M14.8 M17.1 M18.4 M19.9 M19.3 M22.2 M13.6 M
LISN6.1 M8.3 M8.3 M8.3 M9.5 M10.5 M11.6 M12.7 M13.8 M14.7 M14.8 M17.1 M18.4 M19.9 M19.3 M22.2 M13.6 M
BARN20.7 M20.7 M20.7 M21.8 M20.3 M20.4 M22.4 M28.6 M30 M32.2 M29.7 M32.4 M37 M35.9 M35.9 M41.3 M30.4 M
ARYN14.7 M14.7 M14.7 M14.7 M14.7 M14.7 M14.7 M14.7 M12.3 M5.6 M5.3 M5.4 M6 M7.7 M7.7 M6.9 M6.5 M
ORON1.9 M1.9 M1.9 M1.9 M2.2 M2.1 M2.1 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M3.3 M2.5 M

Galderma Group N and related stocks such as Chocoladefabriken Lindt, Chocoladefabriken Lindt, and Barry Callebaut AG Research Development description

My Equities

My Current Equities and Potential Positions

View AllNext
Galderma Group N
GALD
Specialization
Healthcare, Drug Manufacturers - Specialty & Generic
Business AddressZhlerweg 10, Zug,
ExchangeSIX Swiss Exchange
null 145.7

Additional Tools for Galderma Stock Analysis

When running Galderma Group's price analysis, check to measure Galderma Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galderma Group is operating at the current time. Most of Galderma Group's value examination focuses on studying past and present price action to predict the probability of Galderma Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galderma Group's price. Additionally, you may evaluate how the addition of Galderma Group to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY